Encouraging Results Expected in Report June 12th on RIO-Diabetes Trial
Another round of good news about the diet–drug Acomplia (rimonabant) seems likely to be forthcoming on June 12th when researchers publicly report for the first time on results of the RIO-Diabetes trial at the American Diabetes Association’s annual scientific meeting in San Diego.
The year-long Rimonabant in [...]
Sanofi-Aventis, developer of diet drug Acomplia (rimonabant) (Acomplia / Zimulti), said on May 24th it was “examining all legal options” in light of the emergence of three different companies offering generic versions of rimonabant in India.
The development puts Sanofi in the odd position of facing generic competition [...]
Acomplia Report Newsletter Is Renamed the Zimulti Acomplia
The Acomplia (rimonabant) since 2004 the only independent newsletter reporting on the development of diet drug Acomplia (rimonabant), announced today that effective immediately, the online newsletter will be named the Acomplia
The name change was made after the U.S. Food and Drug Administration and manufacturer Sanofi-Aventis [...]
Sanofi-Aventis Seeks to Shut Down News Coverage by the Acomplia Report
Sanofi-Aventis, developer of the much touted diet drug Acomplia (rimonabant) , has announced its intention to try and shut down the independent Acomplia Report, denying hundreds of thousands of obese and overweight individuals this unbiased source of news about the drug and efforts to bring it to [...]
Diet Drug Rimonabant (Acomplia / Zimulti) Approved for Sale in Brazil
Diet drug Acomplia (rimonabant) has been approved by ANVISA, the Brazilian health authority, for sale in Latin America’s largest country, drug-maker Sanofi-Aventis announced on April 26th.
Acomplia was approved by Brazil for use “as an adjunct to diet and exercise for [...]
Acomplia Reported to Show Promise as a Treatment for Prediabetics
A new analysis of the potential of Acomplia (rimonabant) as a treatment for prediabetics was sufficiently encouraging to lead researchers to conclude that a long-term study exploring the role of the new drug in preventing Type 2 diabetes is warranted.
Dr. Julio Rosenstock of the Dallas Diabetes Center in [...]
Zimulti Acomplia Report Covers FDA Panel Meeting on Diet Pill Rimonabant
The make-or-break FDA advisory panel meeting on diet drug rimonabant ( Acomplia (rimonabant) ) will be the subject of team coverage on June 13th by staff of the Zimulti Acomplia , leading independent source of news about rimonabant.
The day-long meeting, which will air concerns [...]
Is No News Good News for Acomplia
In the past month, the new anti–obesity drug Acomplia (rimonabant) has virtually disappeared from the news, leading a number of the millions of overweight men Acomplia (rimonabant) and women who had been hoping it might be available before the end of the year to wonder what’s going on.
Well, what [...]
